<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03880357</url>
  </required_header>
  <id_info>
    <org_study_id>BTCS 1614</org_study_id>
    <nct_id>NCT03880357</nct_id>
  </id_info>
  <brief_title>To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp Psoriasis</brief_title>
  <official_title>Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study Comparing Taro Product to RLD and Both Active Treatments to a Placebo Control in the Treatment of Scalp Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the superiority of the efficacy of the test and reference products over that
      of the placebo control in the treatment of scalp psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, double-blind, randomized, placebo controlled, parallel-group study comparing
      test and reference products to a placebo control in the treatment of scalp psoriasis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment success on the Physician's Global Assessment (PGA) of disease severity</measure>
    <time_frame>Study Week 4 (Day 28 ± 4 days)</time_frame>
    <description>The proportion of subjects in each treatment group with &quot;treatment success&quot; (defined as none or minimal, a score of 0 or 1, within the treatment area) on the PGA of disease severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical success on the Physician's Global Assessment (PASI) of disease severity</measure>
    <time_frame>Study Week 4 (Day 28 ± 4 days)</time_frame>
    <description>The proportion of subjects in each treatment group with &quot;clinical success&quot; (defined as clear or almost clear, a score of 0 or 1, at the target lesion site) on the PASI. Each psoriatic sign of scaling, erythema and plaque elevation should have a score of 0 or 1 for the subject to be considered a clinical success. The target lesion is to be identified at Baseline as the most severe lesion.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Scalp Psoriasis</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Betamethasone Scalp Suspension 0.064%;0.0005% (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of the test product (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone Scalp Suspension 0.064%;0.0005%</intervention_name>
    <description>applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.</description>
    <arm_group_label>Test Product</arm_group_label>
    <other_name>Taclonex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taclonex®</intervention_name>
    <description>applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.</description>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>Calcipotriene and Betamethasone Dipropionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo topical suspension</intervention_name>
    <description>applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant female aged ≥18 years

          -  All male subjects had to agree to use accepted methods of birth control with their
             partners, from the day of the first application of the study drug to 30 days after the
             last application of the study drug

          -  Willing and able to understand and comply with the requirements of the protocol,
             including attendance at the required study visits

          -  A clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least
             10% of the scalp

        Exclusion Criteria:

          -  Female subjects who were pregnant, nursing, or planning to become pregnant during
             study participation

          -  Known hypersensitivity to calcipotriene, betamethasone dipropionate, other
             corticosteroids, or to any ingredients in the study drugs

          -  Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic,
             exfoliative, or pustular psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catawba Research, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 15, 2019</last_update_submitted>
  <last_update_submitted_qc>March 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

